Leslie McCasland, MD
Rheumatology · Jonesboro, ARNPI 1003873019
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Eli Lilly at 47.5% of the total. Reporting peaked in 2019 at $4,999 and has fallen 79.5% since, to $1,024 in 2025.
Across 277 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Amgen$1K
- AbbVie$909
- UCB, Inc.$368
- Johnson & Johnson$366
- Pfizer$334
- plus $1K from 15 others
Across 135 payments — averaging $6065.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$759K
- Janssen Research & Development, LLC$60K
What the payments were for
- Consulting fees$4,06947%
- Food & beverage$4,35651%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $4,069 |
| Amgen(2 entities) | 94 | $1,142 |
| AbbVie | 68 | $909 |
| UCB, Inc. | 20 | $368 |
| Johnson & Johnson | 12 | $366 |
| Pfizer | 16 | $334 |
| Novartis | 11 | $258 |
| GSK | 10 | $247 |
| Lilly USA, LLC | 14 | $241 |
| Genentech USA, Inc. | 7 | $148 |
| Aurinia Pharma U.S., Inc. | 3 | $71 |
| AstraZeneca | 3 | $61 |
| Boehringer Ingelheim | 3 | $61 |
| Organon | 4 | $61 |
| Radius Health, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $43 |
| Sandoz | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALTZ$4,069
How this compares
$8,571 in reported general payments places this provider in the 65th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 110 | $920,994 |
| Enbrel SureclickEtanercept | 93 | $768,633 |
| EnbrelEtanercept | 39 | $292,247 |
| Humira(Cf)Adalimumab | 37 | $270,506 |
| TruximaRituximab-Abbs | 18 | $267,809 |
| RinvoqUpadacitinib | 26 | $156,329 |
| Humira PenAdalimumab | 23 | $150,761 |
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $96,213 |
| SimponiGolimumab | 12 | $85,235 |
| ActemraTocilizumab | 13 | $64,626 |
| Hydroxychloroquine Sulfate | 763 | $27,128 |
| ProliaDenosumab | 11 | $19,120 |
| MethotrexateMethotrexate Sodium | 689 | $12,314 |
| SavellaMilnacipran Hcl | 20 | $10,795 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 385 | $8,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Savella | $909 | $437,63083 claims |
| AmgenEnbrel, Prolia | $1,142 | $311,36750 claims |
| UCB, Inc.Cimzia (2 Pack) | $368 | $96,21317 claims |
| Johnson & JohnsonSimponi | $366 | $85,23512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in Jonesboro
- Beata Filip-MajewskiJonesboro$14K
- Soumyasri KambhatlaJonesboro$705
- Randy RobertsJonesboro$124
- Russell BranumFort Smith$102K
- Cummins LueLittle Rock$76K
- Shailendra SinghSearcy$67K
- Christopher SonntagFayetteville$32K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Noha MohamedConway$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.